Literature DB >> 8955456

Alport's syndrome in 78 patients: epidemiological and clinical study.

H Pajari1, H Kääriäinen, T Muhonen, O Koskimies.   

Abstract

In a nationwide study in Finland, 78 patients, 38 male and 40 female in 25 families, were found to have Alport's syndrome, corresponding to 1 in 53,000 live births. This frequency of clinically manifest Alport's syndrome was much lower than expected from earlier reports. This first sign of the disease was most often haematuria, but was sometimes proteinuria or hearing loss. These signs were detected at a similar median age in both boys and girls, namely 6.2 and 6.0 years, respectively. The patients were followed up over a median period of 12.1 years (range 0.1 - 34.0 years). The clinical course of the disease was more severe in the male subjects than in the female subjects: 53% of the males and 13% of the females developed terminal renal failure at median ages of 24.9 and 31.1 years, respectively. At the last observation, 34% males and 78% females were free of renal insufficiency at median ages of 10.3 and 26.8 years. Hearing loss was detected in 74% of the males and 5% of the females. Regarding the rate of deterioration of renal function, no statistically significant difference was noticed between males and females. The routine use of dialysis and transplantations has dramatically changed the life expectancy of the patients.

Entities:  

Mesh:

Year:  1996        PMID: 8955456     DOI: 10.1111/j.1651-2227.1996.tb13915.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  10 in total

1.  Clinical utility gene card for: Alport syndrome.

Authors:  Jens Michael Hertz; Mads Thomassen; Helen Storey; Frances Flinter
Journal:  Eur J Hum Genet       Date:  2011-12-14       Impact factor: 4.246

2.  Prevalence Estimates of Predicted Pathogenic COL4A3-COL4A5 Variants in a Population Sequencing Database and Their Implications for Alport Syndrome.

Authors:  Joel Gibson; Rachel Fieldhouse; Melanie M Y Chan; Omid Sadeghi-Alavijeh; Leslie Burnett; Valerio Izzi; Anton V Persikov; Daniel P Gale; Helen Storey; Judy Savige
Journal:  J Am Soc Nephrol       Date:  2021-06-18       Impact factor: 14.978

3.  Genetic cause of X-linked Alport syndrome in a family of domestic dogs.

Authors:  Melissa L Cox; George E Lees; Clifford E Kashtan; Keith E Murphy
Journal:  Mamm Genome       Date:  2003-06       Impact factor: 2.957

4.  Alport-leiomyomatosis syndrome requiring subtotal esophagectomy for refractory gastroesophageal reflux disease after childhood partial esophagogastrectomy: a case report.

Authors:  Junya Aoyama; Yutaka Miyawaki; Takuya Kato; Naoto Fujiwara; Hirofumi Sugita; Hiroshi Sato; Masanori Yasuda; Shinichi Sakuramoto; Shigeki Yamaguchi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2019-11-22

5.  Clinical utility gene card for: Alport syndrome - update 2014.

Authors:  Jens Michael Hertz; Mads Thomassen; Helen Storey; Frances Flinter
Journal:  Eur J Hum Genet       Date:  2014-11-12       Impact factor: 4.246

6.  Prevalence of clinical, pathological and molecular features of glomerular basement membrane nephropathy caused by COL4A3 or COL4A4 mutations: a systematic review.

Authors:  Andreas Matthaiou; Tsielestina Poulli; Constantinos Deltas
Journal:  Clin Kidney J       Date:  2020-02-10

7.  Genotype-phenotype correlations for COL4A3-COL4A5 variants resulting in Gly substitutions in Alport syndrome.

Authors:  Joel T Gibson; Mary Huang; Marina Shenelli Croos Dabrera; Krushnam Shukla; Hansjörg Rothe; Pascale Hilbert; Constantinos Deltas; Helen Storey; Beata S Lipska-Ziętkiewicz; Melanie M Y Chan; Omid Sadeghi-Alavijeh; Daniel P Gale; Agne Cerkauskaite; Judy Savige
Journal:  Sci Rep       Date:  2022-02-17       Impact factor: 4.379

8.  Phenotypic heterogeneity in females with X-linked Alport syndrome.

Authors:  Samuel C Allred; Karen E Weck; Adil Gasim; Amy K Mottl
Journal:  Clin Nephrol       Date:  2015-11       Impact factor: 0.975

9.  Low frequency of parental mosaicism in de novo COL4A5 mutations in X-linked Alport syndrome.

Authors:  Ole Magnus Bjorgaas Helle; Torkild Høieggen Pedersen; Lilian Bomme Ousager; Mads Thomassen; Jens Michael Hertz
Journal:  Mol Genet Genomic Med       Date:  2020-08-18       Impact factor: 2.183

10.  Consensus statement on standards and guidelines for the molecular diagnostics of Alport syndrome: refining the ACMG criteria.

Authors:  Judy Savige; Helen Storey; Elizabeth Watson; Jens Michael Hertz; Constantinos Deltas; Alessandra Renieri; Francesca Mari; Pascale Hilbert; Pavlina Plevova; Peter Byers; Agne Cerkauskaite; Martin Gregory; Rimante Cerkauskiene; Danica Galesic Ljubanovic; Francesca Becherucci; Carmela Errichiello; Laura Massella; Valeria Aiello; Rachel Lennon; Louise Hopkinson; Ania Koziell; Adrian Lungu; Hansjorg Martin Rothe; Julia Hoefele; Miriam Zacchia; Tamara Nikuseva Martic; Asheeta Gupta; Albertien van Eerde; Susie Gear; Samuela Landini; Viviana Palazzo; Laith Al-Rabadi; Kathleen Claes; Anniek Corveleyn; Evelien Van Hoof; Micheel van Geel; Maggie Williams; Emma Ashton; Hendica Belge; Elisabeth Ars; Agnieszka Bierzynska; Concetta Gangemi; Beata S Lipska-Ziętkiewicz
Journal:  Eur J Hum Genet       Date:  2021-04-15       Impact factor: 4.246

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.